In addition, the Group's subsidiary Viva Biotech Shanghai was successfully restructured into a joint stock limited company on September 27, 2024, as the Group currently holds approximately 72.9% of ...

By focusing on new targets, novel MOA and new modalities ... peptide technology platform, PROTAC/molecular glue platform, and antibody/large molecule R&D technology platform.

Takeda Pharmaceuticals & Degron Therapeutics (May 2024) – Developing novel molecular glue degraders for oncology, neuroscience, and inflammatory diseases. NEOsphere Biotechnologies & Kymera ...

Monte Rosa Therapeutics’ plan to develop a molecular glue degrader in a wide range of cancers has come unstuck. Biomarker-positive patients were rarer than expected in some tumor types ...

Although many potential molecular glue compounds are being identified through drug discovery methods, only a few have advanced to clinical trials to evaluate their effectiveness in treating diseases.

Unmet needs, market barriers, and future trends in targeted protein degradation. Takeda Pharmaceuticals & Degron Therapeutics (May 2024) – Developing novel molecular glue degraders for oncology, ...